(RTTNews) - Biopharmaceutical company Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced Thursday positive data from its recently completed clinical drug-drug interaction (DDI) study investigating ...
Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose ...
Light blue indicates the substrate-binding cavity inside the CYP enzyme. The CYP enzyme is unable to form a stable interaction with the atropisomer (aS)-CB45 because (aS)-CB45 collides (indicated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results